105,737 research outputs found
Milano 2015. Verso l’Expo e oltre
No full textCinque fotografi sono stati chiamati a documentare cosa è successo delle aree dedicate all'Expo dopo l'evento, Gabriele Basilico / Saragozza, Caludio Gobbi / Hannover, Marco Introini /Lisbona, Maurizio Montaga / ExpoSuisse, Claudio Sabatino / Siviglia
A cura di
Manolo De Giorgi
Andrea Kerbaker
Franco Raggi
Daniela Volpi
Sede Della Mostra:Triennale di Milano
dal 5 novembre al 20 novembre 200
Effects of quetiapine and olanzapine in patients with psychosis and violent behavior: A pilot randomized, open-label, comparative study
No full textObjective: Patients suffering from psychosis are more likely than the general population to commit aggressive acts, but the therapeutics of aggressive behavior are still a matter of debate. Methods: This pilot randomized, open-label study compared the efficacy of quetiapine versus olanzapine in reducing impulsive and aggressive behaviors (primary endpoints) and psychotic symptoms (secondary endpoints) from baseline to days 1, 7, 14, 28, 42, 56, and 70, in 15 violent schizophrenic patients hospitalized in a maximum-security psychiatric hospital. Results: Quetiapine (525±45 mg) and olanzapine (18.5±4.8 mg) were both efficacious in reducing Impulsivity Rating Scale from baseline to day 70. In addition, both treatments reduced the Brief Psychiatric Rating Scale, Positive and Negative Syndrome Scale, and Clinical Global Impression Scale scores at day 70 compared to baseline, and no differences were observed between treatments. Moreover, quetiapine, but not olanzapine, yielded an improvement of depressive symptoms in the items "depression" in Brief Psychiatric Rating Scale and "blunted affect" in Positive and Negative Syndrome Scale. Modified Overt Aggression Scale scores were also decreased from baseline to the endpoint, but due to the limited number of patients, it was not possible to detect a significant difference. Conclusion: In this pilot study, quetiapine and olanzapine equally decreased impulsive and psychotic symptoms after 8 weeks of treatment. Double-blind, large studies are needed to confirm the validity of these two treatments in highly aggressive and violent schizophrenic patients. © 2014 Gobbi et al
Virtual interactive practice™: A strategy to enhance learning and competence in health care students
No full textThis paper reports the processes and initial outcomes of a pilot study which investigated a week long ‘virtual’ children’s ward experience for nursing students. Providing sufficient and meaningful experiences which enable students to quickly and effectively achieve competence in diverse areas of practice is often frustrated by the realities of available clinical experiences. Our response to this challenge was to more fully exploit and evaluate technologies which can be used to provide these learning experiences. Students experienced ‘real time’ scenario based work involving SIM-MAN; interactive information technology scenarios, critical incidents, master classes, video conferencing, and observational skill development exercises. Evaluation methodologies included observation of student performance, competence self rating scales; analysis of videotaped performance episodes and other data generated through the learning activities and lived experience accounts of participants. Initial findings indicate(1) statistically significant improvements in student competence measured through self reports; and (2) evidence of improvement gleaned from observed accounts, video analysis and qualitative evaluative comments. The final outcomes, including work with a control group, will be available for Conference
PoliHydra/hydra: fully coupled implementation
No full text<p>The code in this release is the base for</p>
<blockquote>
<p><strong>G. Gobbi, C. Colombo, S. Miccoli, L. Vergani (2019)</strong>. A fully coupled implementation of hydrogen embrittlement in FE analysis. Advances in Engineering Software, 135. <a href="https://doi.org/10.1016/j.advengsoft.2019.04.004">doi:10.1016/j.advengsoft.2019.04.004</a></p>
</blockquote>
PoliHydra/hydra: weakly coupled implementation
No full text<p>The code in this release was used for the examples in</p>
<blockquote>
<p>G. Gobbi, C. Colombo, S. Miccoli, L. Vergani (2018). A weakly coupled implementation of hydrogen embrittlement in FE analysis. Finite Elements in Analysis and Design, 141, pp. 17-25. <a href="https://doi.org/10.1016/j.finel.2017.11.010">doi:10.1016/j.finel.2017.11.010</a></p>
</blockquote>
Erratum: Patients with Severe Obesity during the COVID- 19 Pandemic: How to Maintain an Adequate Multidisciplinary Nutritional Rehabilitation Program? (Obes Facts. (2021) DOI: 10.1159/000513283)
No full textIn the article by De Amicis et al. entitled "Patients with Severe Obesity during the COVID- 19 Pandemic: How to Maintain an Adequate Multidisciplinary Nutritional Rehabilitation Program?" [Obes Facts. 2021, DOI: 10.1159/000513283], the author list is incorrect. The correct author list is: De Amicis R. Cancello R. Capodaglio P. Gobbi M. Brunani A. Gilardini L. Castelnuovo G. Molinari E. Barbieri V. Mambrini S.P. Battezzati A. Bertoli S
Nursing practice as bricoleur activity: a concept explored
No full textThe debates concerning the nature of nursing practice are often rooted in tensions between artistic, scientific and magical/mythical practice. It is within this context that the case is argued for considering that nursing practice involves bricoleur activity. This stance, which is derived from the work of Levi-Strauss, conceives elements of nursing practice as an embodied, bricoleur practice where practitioners draw on the 'shards and fragments' of the situation-at-hand to resolve the needs of the individual patient for whom they care. This conceptualisation of nursing practice will be analysed with a particular emphasis on its implication for nursing epistemology, pedagogy and praxis. The evidence to support this argument is drawn from empirical work that investigated nurses' use of intuition, the work of Levi-Strauss, and issues in nursing epistemology and ontology. The paper itself is written from the perspective of a bricoleur who uses 'bits and pieces' from the domains of nursing, philosophy, psychology, education, sociology and anthropology
Differential function of melatonin MT1 and MT2 receptors in REM and NREM sleep
No full textThe pathophysiological function of the G-protein coupled melatonin MT1 and MT2 receptors has not yet been well-clarified. Recent advancements using selective MT1/ MT2 receptor ligands and MT1/MT2 receptor knockout mice have suggested that the activation of the MT1 receptors are mainly implicated in the regulation of rapid eye movement (REM) sleep, whereas the MT2 receptors selectively increase non-REM (NREM) sleep. Studies in mutant mice show that MT1 knockout mice have an increase in NREM sleep and a decrease in REM sleep, while MT2 knockout mice a decrease in NREM sleep. The localization of MT1 receptors is also distinct from MT2 receptors; for example, MT2 receptors are located in the reticular thalamus (NREM area), while the MT1 receptors in the Locus Coeruleus and lateral hypothalamus (REM areas). Altogether, these findings suggest that these two receptors not only have a very specialized function in sleep, but that they may also modulate opposing effects. These data also suggest that mixed MT1-MT2 receptors ligands are not clinically recommended given their opposite roles in physiological functions, confirmed by the modest effects of melatonin or MT1/MT2 non-selective agonists when used in both preclinical and clinical studies as hypnotic drugs. In sum, MT1 and MT2 receptors have specific roles in the modulation of sleep, and consequently, selective ligands with agonist, antagonist, or partial agonist properties could have therapeutic potential for sleep; while the MT2 agonists or partial agonists might be indicated for NREM-related sleep and/or anxiety disorders, the MT1 agonists or partial agonists might be so for REM-related sleep disorders. Furthermore, MT1 but not MT2 receptors seem involved in the regulation of the circadian rhythm. Future research will help further develop MT1 and/or MT2 receptors as targets for neuropsychopharmacology drug development
Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: A novel target in psychopharmacology
No full textBackground: Melatonin (MLT) is a pleiotropic neurohormone controlling many physiological processes and whose dysfunction may contribute to several different diseases, such as neurodegenerative diseases, circadian and mood disorders, insomnia, type 2 diabetes and pain. Melatonin is synthesized by the pineal gland during the night and acts through 2 G-protein coupled receptors (GPCRs), MT1 (MEL1a) and MT2 (MEL1b). Although a bulk of research has examined the physiopathological effects of MLT, few studies have investigated the selective role played by MT1 and MT2 receptors. Here we have reviewed current knowledge about the implications of MT2 receptors in brain functions. Methods: We searched PubMed, Web of Science, Scopus, Google Scholar and articles reference lists for studies on MT2 receptor ligands in sleep, anxiety, neuropsychiatric diseases and psychopharmacology, including genetic studies on the MTNR1B gene, which encodes the melatonin MT2 receptor. Results: These studies demonstrate that MT2 receptors are involved in the pathophysiology and pharmacology of sleep disorders, anxiety, depression, Alzheimer disease and pain and that selective MT2 receptor agonists show hypnotic and anxiolytic properties. Limitations: Studies examining the role of MT2 receptors in psychopharmacology are still limited. Conclusion: The development of novel selective MT2 receptor ligands, together with further preclinical in vivo studies, may clarify the role of this receptor in brain function and psychopharmacology. The superfamily of GPCRs has proven to be among the most successful drug targets and, consequently, MT2 receptors have great potential for pioneer drug discovery in the treatment of mental diseases for which limited therapeutic targets are currently available. © 2014 Canadian Medical Association
- …
